title: Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.
abstract: Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.
authors.affiliation: Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
authors.forename: Britta
authors.initials: B
authors.lastname: Auel
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Thomas
authors.initials: T
authors.lastname: Geer
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Moehler
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
authors.forename: Ralph
authors.initials: R
authors.lastname: Naumann
authors.forename: Igor
authors.initials: I
authors.lastname: Blau
authors.forename: Mathias
authors.initials: M
authors.lastname: Hänel
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Knauf
authors.forename: Holger
authors.initials: H
authors.lastname: Nückel
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Salwender
authors.forename: Christof
authors.initials: C
authors.lastname: Scheid
authors.forename: Katja
authors.initials: K
authors.lastname: Weisel
authors.forename: Marcus
authors.initials: M
authors.lastname: Gorschlüter
authors.forename: Axel
authors.initials: A
authors.lastname: Glasmacher
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
keywords: Blood Transfusion Medicine; Dexamethasone; Hematology; Human Genetics; Idarubicin; Medicine & Public Health; Myeloma; Oncology; Thalidomide; Vinorelbine